Observation on the curative effect of Qingdu powder applied by Yi medicine on dampness-heat obstruction syndrome of acute gouty arthritis

Phase 1

Recruiting

• Conditions: Gouty Arthritis

• Registration Number: ITMCTR2100004263
• Lead Sponsor: Yunnan Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Those who meet the diagnostic criteria of Western medicine for acute gouty arthritis and the syndrome differentiation criteria of traditional Chinese medicine for dampness-heat obstruction.
(2) The age range is from 18 to 70, and gender is not limited.
(3) The course of the attack is less than 5 days.
(4) No ulceration of the skin at the site of arthritis.
(5) The joint pain sites are knee joint, ankle joint or the first metatarsophalangeal joint.
(6) Patients are willing to be tested and give informed consent.

Exclusion Criteria

(1) Secondary gout, joint lesions caused by diseases such as rheumatoid arthritis, silver-dural arthritis, pseudogout and lupus erythematosus. Chemotherapy, radiotherapy, acute obstructive nephropathy and other joint lesions;
(2) Patients with advanced deformity, disability, loss of labor force, and cardiovascular and cerebrovascular diseases induced by pain;
(3) Severe heart, brain, liver, kidney and other complications or other serious primary diseases, such as tumor or AIDS;
(4) Pregnant and lactating women;
(5) Unbearable severe joint pain (patient rating 10);
(6) People with mental or legal disabilities;
(7) People with allergic constitution (especially those who are allergic to plaster) and known to be allergic to the components of this medicine;
(8) According to the researcher's judgment, other lesions that reduce the possibility of enrolment or complicate enrolment, such as frequent changes in the work environment, may easily lead to loss of follow-up;
(9) Participating in other clinical trials.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
C Reactive Protein;TCM syndrome scoring;Pain degree VAS score;Erythrocyte Sedimentation Rate;Blood Routine Examination;Musculoskeletal Ultrasound;